Pembrolizumab regimen extends survival in advanced esophageal cancer

The addition of pembrolizumab to first-line chemotherapy extended OS and PFS among patients with locally advanced or metastatic esophageal cancer, according to the agent’s manufacturer.

https://www.healio.com/news/hematology-oncology/20200819/pembrolizumab-regimen-extends-survival-in-advanced-esophageal-cancer

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *